Cell line · CVCL_0218
Papers84
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 84
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| IFNAR1 stabilization sustains CD8+ T cell persistence in IFN-high colorectal cancer liver metastases. | Sci Adv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Discovery and Optimization of AMT-676, a CDH17-Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Combining fruquintinib with TAS-102 as a promising strategy: antitumor activity in preclinical colorectal and gastric cancer xenograft models. | BMC Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Viral mimicry redirects immunosuppressed colorectal tumour landscapes towards a proinflammatory and CMS1-like regenerative state. | Commun Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A fully human pan VL9 HLA-E TCRm antibody enables functional dissection of HLA-E biology and checkpoint signaling. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Phytochemical study of Homalanthus giganteus: isolation, antiproliferative activity, and computational mechanistic insights of tigliane diterpenes against colorectal cancer. | Pharm Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mediator Kinase Inhibitor Selectivity and Activity in Colorectal Cancer. | ACS Chem Biol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting Oncofoetal Chondroitin Sulphate Allows Identification of Tumour-Derived Extracellular Vesicles. | J Extracell Vesicles | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Clonal dispersal is associated with tumor heterogeneity and poor prognosis in colorectal cancer. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| circ_0004662 contributes to colorectal cancer progression by interacting with hnRNPM. | Int J Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Epigenome Reprogramming Through H3K27 and H3K4 Trimethylation as a Resistance Mechanism to DNA Methylation Inhibition in BRAFV600E-Mutated Colorectal Cancer. | Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| HTS384 NCI60: The Next Phase of the NCI60 Screen. | Cancer Res | 2024 | Cellosaurus cites it, and its Methods give the RRID and name the line | PubMed | |
| Epigenomic analysis reveals a unique DNA methylation program of metastasis-competent circulating tumor cells in colorectal cancer. | Sci Rep | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy. | Cell | 2023 | Its Methods give the RRID and name the line | PubMed | |
| AMT-562, a Novel HER3-targeting Antibody-Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors. | Mol Cancer Ther | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Identification of Membrane-expressed CAPRIN-1 as a Novel and Universal Cancer Target, and Generation of a Therapeutic Anti-CAPRIN-1 Antibody TRK-950. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| High anti-tumor activity of a novel alpha-fetoprotein-maytansinoid conjugate targeting alpha-fetoprotein receptors in colorectal cancer xenograft model. | Cancer Cell Int | 2023 | Its Methods give the RRID and name the line | PubMed | |
| De novo sphingolipid biosynthesis necessitates detoxification in cancer cells. | Cell Rep | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0218/papers